Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TMO 
Thermo Fisher Scientific Inc (TMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: TMO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
31 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $555.57
1 Year Target Price $555.57
| 18 | Strong Buy |
| 7 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.05% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 181.05B USD | Price to earnings Ratio 27.7 | 1Y Target Price 555.57 |
Price to earnings Ratio 27.7 | 1Y Target Price 555.57 | ||
Volume (30-day avg) 31 | Beta 0.76 | 52 Weeks Range 385.46 - 622.13 | Updated Date 09/14/2025 |
52 Weeks Range 385.46 - 622.13 | Updated Date 09/14/2025 | ||
Dividends yield (FY) 0.33% | Basic EPS (TTM) 17.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.24% | Operating Margin (TTM) 17.84% |
Management Effectiveness
Return on Assets (TTM) 4.97% | Return on Equity (TTM) 13.42% |
Valuation
Trailing PE 27.7 | Forward PE 19.49 | Enterprise Value 209888907534 | Price to Sales(TTM) 4.19 |
Enterprise Value 209888907534 | Price to Sales(TTM) 4.19 | ||
Enterprise Value to Revenue 4.86 | Enterprise Value to EBITDA 18.63 | Shares Outstanding 377612000 | Shares Floating 376739837 |
Shares Outstanding 377612000 | Shares Floating 376739837 | ||
Percent Insiders 0.16 | Percent Institutions 91.87 |
Upturn AI SWOT
Thermo Fisher Scientific Inc
Company Overview
History and Background
Thermo Fisher Scientific Inc. was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Thermo Electron, founded in 1956, focused on analytical instruments, while Fisher Scientific, established in 1902, distributed laboratory equipment and chemicals. This merger created a comprehensive life sciences and laboratory solutions provider.
Core Business Areas
- Life Sciences Solutions: Develops and manufactures reagents, instruments, and consumables for biological and medical research, as well as clinical diagnostics. Focuses on areas like cell biology, genetic analysis, and protein research.
- Analytical Instruments: Provides instruments and related services for laboratory, environmental, and industrial applications. Includes mass spectrometry, chromatography, and spectroscopy products.
- Specialty Diagnostics: Offers diagnostic test kits, reagents, and instruments for clinical laboratories and healthcare providers. Addresses areas like allergy, autoimmune, and infectious disease testing.
- Laboratory Products and Biopharma Services: Supplies a wide range of laboratory equipment, consumables, and chemicals. It also provides bioproduction and related research services to pharmaceutical and biotechnology companies.
Leadership and Structure
Marc N. Casper is the Chairman, President, and Chief Executive Officer. The organizational structure is divisional, reflecting the core business areas. They have a global team of senior executive leaders responsible for individual segments.
Top Products and Market Share
Key Offerings
- Product Name 1: Mass Spectrometry Instruments: Used for chemical analysis across industries. Thermo Fisher holds a significant share in the mass spectrometry market. Competitors include Agilent Technologies (A) and Bruker (BRKR).
- Product Name 2: Chromatography Systems: Utilized for separating and analyzing complex mixtures. Thermo Fisher is a major player in this market. Competitors include Agilent Technologies (A) and Waters Corporation (WAT).
- Product Name 3: PCR Instruments & Reagents: A core part of molecular biology and diagnostics, these products are essential in research and clinical settings. Thermo Fisher is a major player in this market. Competitors include QIAGEN (QGEN) and Roche (ROG.SW).
Market Dynamics
Industry Overview
The life sciences and diagnostics industry is driven by increasing R&D spending, aging populations, and growing demand for personalized medicine. Technological advancements like genomics and proteomics are fueling growth. The industry is highly competitive and fragmented.
Positioning
Thermo Fisher Scientific is a leading player in the industry, with a broad product portfolio and a strong global presence. Its size and scale give it a competitive advantage, including pricing power and cost efficiencies.
Total Addressable Market (TAM)
The estimated total addressable market is several hundred billion USD. Thermo Fisher is positioned to continue capturing and growing market share across its segments.
Upturn SWOT Analysis
Strengths
- Broad Product Portfolio
- Strong Brand Recognition
- Global Reach
- Extensive Customer Base
- Innovation in R&D
Weaknesses
- Integration Challenges from Acquisitions
- High Debt Levels
- Dependence on R&D Spending
- Exposure to Economic Fluctuations
Opportunities
- Growth in Emerging Markets
- Expansion in Personalized Medicine
- Increased Demand for Bioproduction
- Advancements in Genomics and Proteomics
Threats
- Intense Competition
- Patent Expirations
- Regulatory Changes
- Economic Downturns
- Supply chain disruption
Competitors and Market Share
Key Competitors
- A
- WAT
- DHR
- ILMN
Competitive Landscape
Thermo Fisher Scientific has a broader product portfolio than most of its competitors, which gives it a competitive advantage. Its scale and global reach also provide it with cost efficiencies and market access.
Major Acquisitions
PPD, Inc.
- Year: 2021
- Acquisition Price (USD millions): 17400
- Strategic Rationale: Expanded capabilities in clinical research services, increasing addressable market and creating synergies with existing biopharma services.
Brammer Bio
- Year: 2019
- Acquisition Price (USD millions): 1700
- Strategic Rationale: Enhanced capabilities in gene therapy manufacturing, supporting the growing demand for cell and gene therapies.
Growth Trajectory and Initiatives
Historical Growth: Thermo Fisher Scientific has grown significantly through a combination of organic growth and strategic acquisitions.
Future Projections: Analysts expect Thermo Fisher Scientific to continue to grow at a healthy pace, driven by its strong market position and favorable industry trends.
Recent Initiatives: Recent initiatives include acquisitions to expand its product portfolio and geographic reach, as well as investments in R&D to develop new products and technologies.
Summary
Thermo Fisher Scientific is a fundamentally strong company with a well-diversified business and a leading position in the life sciences and diagnostics industry. Its scale, product breadth, and global reach give it a competitive advantage. Risks include high debt levels, integration challenges from acquisitions, and regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Thermo Fisher Scientific Inc
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1978-01-13 | Chairman, President & CEO Mr. Marc N. Casper | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 125000 | Website https://www.thermofisher.com |
Full time employees 125000 | Website https://www.thermofisher.com | ||
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.